MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity
暂无分享,去创建一个
C. Bolchini | Sandro Bottaro | A. Franke | Giuseppe Converso | V. Rimoldi | S. Duga | L. Pattini | F. Degenhardt | R. Asselta | A. Gerussi | P. Invernizzi | E. Paraboschi | G. Tettamanzi | A. Brunati | N. Ziliotto | Claudio Cappadona | Francesco Tartaglia | Giulia Montorsi | E. Tinelli | Francesca Carloni | R. Patti | Andrea Azimonti | Daniele Brenna | Charlotte Cameroni | Giovanni Campanaro | Giacomo Cavadini | Martina Ciravegna | Antonio Composto | Pierluigi Corbella | Davide D’Eugenio | Giovanna Dal Rì | Sofia Maria Di Giorgio | Maria Chiara Grondelli | Lorenza Guerrera | Georges Laffoucriere | Beatrice Lando | Leandro Lopedote | Benedetta Maizza | Elettra Marconi | Carlotta Mariola | G. Matronola | Luca Maria Menga | Antonio Papatolo | Lorenzo Profeta | Vera Rebasti | Alice Smidili | Sofia Maria Tarchi | Riccardo Stuani | E. Marconi | S. M. Tarchi | F. Carloni | L. Profeta | M. C. Grondelli | A. Papatolo
[1] Mattia G. Bergomi,et al. Mapping the human genetic architecture of COVID-19 , 2021, Nature.
[2] K. Vanhoorelbeke,et al. First report of a de novo iTTP episode associated with an mRNA‐based anti‐COVID‐19 vaccination , 2021, Journal of Thrombosis and Haemostasis.
[3] S. Kaleci,et al. COVID‐19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence , 2021, Journal of clinical laboratory analysis.
[4] I. Martín-Loeches,et al. ADAMTS13 regulation of VWF multimer distribution in severe COVID‐19 , 2021, Journal of Thrombosis and Haemostasis.
[5] M. Gisslén,et al. Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19 , 2021, Thrombosis Research.
[6] S. Scherer,et al. Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. , 2021, The Journal of clinical investigation.
[7] T. Mirault,et al. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance , 2021, Angiogenesis.
[8] E. Simon,et al. Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination , 2021, The American Journal of Emergency Medicine.
[9] Ruth I. Tennen,et al. Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity , 2021, Nature Genetics.
[10] P. Marco,et al. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19 , 2021, Journal of Thrombosis and Thrombolysis.
[11] A. Coppola,et al. Homocysteine (Hcy) assessment to predict outcomes of hospitalized Covid-19 patients: a multicenter study on 313 Covid-19 patients , 2021, Clinical chemistry and laboratory medicine.
[12] V. Mootha,et al. SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication , 2021, Nature Communications.
[13] C. Tcherakian,et al. ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 , 2021, Thrombosis Research.
[14] Gregory J Krause,et al. Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients , 2021, TH Open.
[15] I. Martín-Loeches,et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation , 2020, British journal of haematology.
[16] Alexander Hanbo Li,et al. Genome-wide analysis in 756,646 individuals provides first genetic evidence that ACE2 expression influences COVID-19 risk and yields genetic risk scores predictive of severe disease , 2020, medRxiv.
[17] Gustavo Faissol Janot de Matos,et al. Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study , 2020, PloS one.
[18] A. Alexandrov,et al. COVID-19 and cerebrovascular diseases: a comprehensive overview , 2020, Therapeutic advances in neurological disorders.
[19] S. Laporte,et al. Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data , 2020, Data in Brief.
[20] Alexander Hanbo Li,et al. A catalog of associations between rare coding variants and COVID-19 outcomes , 2020, medRxiv.
[21] J. Knight,et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 , 2020, Science Translational Medicine.
[22] Barbara B. Shih,et al. Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.
[23] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[24] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[25] M. Karst,et al. Life-threatening course in coronavirus disease 2019 (COVID-19): Is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism and hyperhomocysteinemia? , 2020, Medical Hypotheses.
[26] G. Grasselli,et al. Hemostatic alterations in COVID-19 , 2020, Haematologica.
[27] D. Cummings,et al. Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries , 2020, medRxiv.
[28] Jonathan A Stefely,et al. Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism , 2020, American journal of hematology.
[29] J. Merrill,et al. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications , 2020, Nature Reviews Rheumatology.
[30] O. Olivieri,et al. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19 , 2020, Thrombosis Research.
[31] Xiaowei Yan,et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients , 2020, Journal of Thrombosis and Thrombolysis.
[32] G. Dangas,et al. Viral Coagulopathy in Patients With COVID-19: Treatment and Care , 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[33] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[34] C. D. Dela Cruz,et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.
[35] J. Erdmann,et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.
[36] P. Emery,et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.
[37] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[38] Koichi Yuki,et al. COVID-19 pathophysiology: A review , 2020, Clinical Immunology.
[39] G. Grasselli,et al. Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.
[40] A. Mantovani,et al. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy , 2020, medRxiv.
[41] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[42] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[43] P. Visscher,et al. Genome-wide association study of medication-use and associated disease in the UK Biobank , 2019, Nature Communications.
[44] L. Liang,et al. Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis , 2019, Respiratory Research.
[45] Brian E. Cade,et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program , 2019, Nature.
[46] C McRae,et al. Myocardial infarction. , 2019, Australian family physician.
[47] O. Andreassen,et al. A global overview of pleiotropy and genetic architecture in complex traits , 2019, Nature Genetics.
[48] Timothy Shin Heng Mak,et al. Tutorial: a guide to performing polygenic risk score analyses , 2018, bioRxiv.
[49] William J. Astle,et al. Allelic Landscape of Human Blood Cell Trait Variation and Links , 2016 .
[50] P. James,et al. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms , 2016, Journal of thrombosis and haemostasis : JTH.
[51] Carson C Chow,et al. Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.
[52] A. Keinan,et al. XWAS: A Software Toolset for Genetic Data Analysis and Association Studies of the X Chromosome , 2014, bioRxiv.
[53] Christian Gieger,et al. Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.
[54] P. Reitsma,et al. Genetics of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.
[55] Alberto Piazza,et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants , 2009, Nature Genetics.
[56] X. Zheng,et al. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells , 2008, Journal of thrombosis and haemostasis : JTH.
[57] Amitabh Sharma,et al. Mining literature for a comprehensive pathway analysis: A case study for retrieval of homocysteine related genes for genetic and epigenetic studies , 2006, Lipids in Health and Disease.
[58] Kristin K Nicodemus,et al. Comparison of type I error for multiple test corrections in large single-nucleotide polymorphism studies using principal components versus haplotype blocking algorithms , 2005, BMC Genetics.
[59] A. Bernardo,et al. Hemostasis, Thrombosis, and Vascular Biology , 2022 .
[60] D. Nyholt. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.
[61] P. Durand,et al. Acute methionine load‐induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage‐derived tissue factor activity in rats , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] E. Lander,et al. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results , 1995, Nature Genetics.
[63] G. Rodgers,et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[64] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[65] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[66] S. Stouffer. Adjustment during army life , 1977 .
[67] J. Hemelrijk,et al. Some remarks on the combination of independent tests , 1953 .